Lambda Biologics offers 3D AtheroVasc™ Nanomatrix Sheet Models to support researchers and pharmaceutical partners in exploring the complex mechanisms of atherosclerosis and developing next-generation cardiovascular therapies. Built with biomimetic two- or three-layer vascular structures and an ECM-mimicking nanomatrix, these models replicate key stages of atherosclerosis with exceptional precision - bridging the gap between in vitro and in vivo studies. Our platform enables high-throughput, ethical, and cost-efficient research - empowering discovery and accelerating translational outcomes.
Price | |
Organism | Human |
Product Type | Engineered 3D sheet type |
Tissue | Vasculature |
Disease | Atherosclerosis |
Applications
Drug screening
With the global rise of K-beauty, the cosmetics industry continues to grow steadily. Since the ban on animal testing for cosmetics in Korea in 2017, various alternative testing methods have...
Traditional microscopy methods often require fluorescent labeling to analyze cellular structures, which can be time-consuming and invasive. In contrast, our HT-X1 system allows for high-resolution visualization of cellular morphology without...
Traditional protein analysis has primarily focused on quantifying expression levels within tissue samples. However, recent advances in spatial analysis techniques have shifted attention toward evaluating not only expression levels, but...
We conducted a study focused on identifying disease-related markers using patient-derived tissue samples. However, traditional methods limited our ability to analyze multiple candidate markers simultaneously, and the limited availability of...
Single-, double-, or triple-layer customized constructs.
AtheroVascTM has been validated with conventional (statins, sirolimus), novel (curcumin, colchicine) candidates.
AtheroVascTM is designed for high-throughput screening, allowing parallel drug candidate testing in standard 48- or 96-well plate formats 384-well plate formats in development.
The layer-by-layer fabrication method ensure consistent results and high replicative potential.
AtheroVascTM’s ability to provide human-relevant data supports the pharmaceutical industry’s push for animal model alternatives and more predictive preclinical drug screening tools.
Atherosclerosis is a leading cause of cardiovascular morbidity and mortality, yet current models are limited by high costs, extended induction periods, and insufficient replication of human disease mechanisms. To address these challenges, we have developed an innovative in vitro model – tissue-engineered vascular sheets with atherosclerosis (VSA). This model faithfully recapitulates the native three-layered arterial structure and key disease features, including endothelial dysfunction, inflammatory macrophage infiltration, and foam cell formation.
A major strength of the VSA is its adaptability to multi-well plate formats for inflammation assays. This scalable platform enables robust, cost-effective, high-throughput screening, with a specific focus on evaluating the anti-inflammatory effects of potential therapeutics. By facilitating real-time monitoring and quantification of inflammatory responses, our inflammation assay is critical for rapidly identifying compounds that can mitigate the progression of atherosclerosis.
The 3D AtheroVasc Nanomatirx Sheet Models are being developed in two distinct series to address a wide range of research and therapeutic development needs.
3D AtheroVascTM DL Nanomatrix Sheet, replicates the tunica intima and tunica media, providing a robust platform for studying endothelial function, smooth muscle interactions, and atherosclerosis pathologies.
3D AtheroVascTM TL Nanomatrix Sheet incorporates an additional tunica adventitia layer, enabling researchers to explore complex multi-layered interactions and atherosclerotic processes.
These two series offer unparalleled versatility and physiological relevance, empowering researchers and pharmaceutical developers to target specific stages of vascular disease with precision.
The 3D AtheroVascTM Sheet Models are being developed in two distinct series to address a wide range of research and therapeutic development needs.
3D AtheroVascTM DL Sheet, replicates the tunica intima and tunica media, providing a robust platform for studying endothelial function, smooth muscle interactions, and atherosclerosis pathologies.
3D AtheroVascTM TL Sheet, incorporates an additional tunica adventitia layer, enabling researchers to explore complex multi-layered interactions and atherosclerotic processes.
These two series offer unparalleled versatility and physiological relevance, empowering researchers and pharmaceutical developers to target specific stages of vascular disease with precision.
Our inflammation assays comprehensively evaluate anti-inflammatory agents across pivotal stages of atherogenesis and early atherosclerosis development detecting presence and degree of vascular inflammation, activity of specific inflammatory pathways and response to anti-inflammatory therapies.
The 3D AtheroVascTM Sheet Model provides a scientifically advanced platform for evaluating drug efficacy across distinct stages of atherosclerosis. By simulating inflammation at specific pathological states and treatment time points, our system enables targeted assessment of prevention, intervention, and therapeutic reversal strategies.
Assays based on Model 1-3 are categorized based on when the drug is applied—before, during, or after inflammatory stimuli—allowing precise, translational insights into therapeutic performance.
Pre-treatment (Pre)
Drug administered before inflammatory stimuli.
Simultaneous (Sim)
Drug introduced concurrently with inflammatory triggers to evaluate immediate intervention potential during inflammation.
Post-treatment (Post)
Drug applied after inflammation has been initiated to determine its ability to reverse or mitigate ongoing inflammation.
